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Abstract
Background: The UK Risk Sharing Scheme (RSS) provided information on the effect of first-line
multiple sclerosis (MS) disease-modifying treatments on long-term disability.
Objective: The aim is to provide results specific to glatiramer acetate (GA; CopaxoneV
R
) from the final
10-year analysis of the RSS.
Methods: A Markov model was used to assess clinical effectiveness measured as Expanded Disability
Status Scale (EDSS) progression and utility loss. Untreated patients from the British Columbia MS
cohort (1980–1995) were used as a ‘virtual comparator’ group. A separate Markov model assessed cost-
effectiveness, based on a 50-year time horizon (with a 50% treatment waning effect imposed at 10 years)
and using NHS list price (£513.95 per 28 days). Results were expressed in quality-adjusted life years
(QALYs).
Results: In total, 755 patients with relapsing–remitting MS (RRMS) received GA, with a mean
follow-up of 7.1 (standard deviation 1.3) years. EDSS progression was reduced by 23% (progression
ratio 76.7, 95% confidence interval [CI] 69.0–84.3) and utility loss by 39% (progression ratio 61.0, 95%
CI 52.7–69.3) compared with no treatment. There was no persistent waning in GA treatment effect over
time (EDSS: p¼ 0.093; utilities: p¼ 0.119). The cost per QALY was £17,841.
Conclusion: GA had a beneficial effect on long-term disability and was a cost-effective treatment for
RRMS.
Keywords: Relapsing–remitting multiple sclerosis, real-world evidence, disease-modifying therapy,
disability
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Introduction
Multiple sclerosis (MS) is a neurological disease
that imposes a considerable burden on patients,
healthcare systems and society.1–4 At diagnosis,
relapsing forms of MS are most prevalent,5 with
relapsing–remitting MS (RRMS) accounting for
around 80% of MS cases.6 RRMS is characterised
by periodic, transient relapses interspersed with peri-
ods of recovery and an accumulation of disability
associated with incomplete recovery from relapses.7
Disease-modifying treatments (DMTs) for MS, such
as glatiramer acetate (GA) and the beta interferons,
have been available since the late 1990s, and are able
to reduce the rate of relapses in RRMS.8 GA, under
the brand name CopaxoneV
R
, has accumulated more
than 2 million patient-years of experience in people
with relapsing forms of MS over the past two deca-
des.9 GA is classified as a non-biological complex
drug (NBCD), with a composition that is dependent
on a closely controlled manufacturing process.10–12
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The exact mechanism of action for GA is not fully
understood, but it is thought to modify immune pro-
cesses responsible for the pathogenesis of MS.13,14
CopaxoneV
R
and the beta interferons (AvonexV
R
,
BetaferonV
R
, RebifV
R
) were assessed by the National
Institute for Clinical Excellence (NICE; now known
as National Institute for Health and Care Excellence)
in 2002,15 the first DMTs for MS to be appraised by
NICE. In response to the limitations highlighted
during this appraisal regarding the extrapolation of
long-term trends from short-term clinical studies,
the Risk Sharing Scheme (RSS) was established.16
The RSS provided cost-effective provision of these
DMTs to the National Health Service (NHS)
(through discounted costs for some products includ-
ing CopaxoneV
R
) while collecting long-term data
on their clinical and cost-effectiveness through a
10-year observational study.16 The RSS included
mechanisms for price changes based on interim anal-
yses to ensure that the scheme DMTs continued to
be supplied at a cost-effective price.16 CopaxoneV
R
,
in line with the other drugs within the RSS, was
assigned an individual cost-effectiveness target for
reduction of Expanded Disability Status Scale
(EDSS) worsening predicated on data from its reg-
istration studies. Based on its performance in
exceeding its target, CopaxoneV
R
was granted an
increase to list price after the scheduled analyses at
year 6 demonstrated its cost-effectiveness.17,18
The aggregate results for all four DMTs in the RSS
at 2 years,19 6 years,20 and, recently, the final
10-year analysis have been published.21 For the
RSS DMTs in aggregate, the 10-year analysis,
using the Markov model, reported a 14% reduction
in EDSS progression (ratio 86%) and 31% reduc-
tion in utility loss (ratio 69%) in patients with
RRMS. The treatment effect corresponded to an
absolute reduction of 0.25 EDSS units compared
with that predicted by natural history. It was also
found that while the treatment effect of the DMTs
was maintained over 10 years, effectiveness
appeared to decrease with time.21 The results for
GA alone in the RSS are presented in this paper,
focussing on the clinical and cost-effectiveness of
this DMT over 10 years of real-world usage.
Methods
RSS methodology
Full details on the methodology of the RSS have
been published previously.20,22 In brief, eligibility
for entry into the RSS was governed by the 2001
Association of British Neurologists (ABN) criteria
which, for RRMS, were: aged 18 years or older;
two clinically significant relapses in the previous
2 years; and an EDSS score 5.5.16 Patients were
recruited at 72 sites between January 2002 and July
2005. Treatment allocation for eligible patients was
through patient and physician preference at the time
of prescribing. Patients had annual reviews, with
assessment of EDSS carried out irrespective of
changes to treatment (except when in relapse).
Comparator cohort
The RSS included no untreated/placebo patients and
instead relied on a ‘virtual comparator’ group based
on data from untreated patients in the British
Columbia MS (BCMS) database (1980–1995) who
met the ABN 2001 eligibility criteria.22 Comparison
of baseline characteristics between RSS and BCMS
patients was assessed by t-test and Chi-square test,
as appropriate. Transition probabilities for EDSS
progression were derived from the BCMS data and
used to drive a continuous Markov model that mod-
elled the expected progression of disability without
DMT treatment in the RSS cohort. The model
adjusted for differences in baseline characteristics
between the BCMS cohort and the RSS population.
The model used EDSS figures rounded down to the
nearest integer (for half point scores), age of onset as
a covariate (<28 years or 28 years), and had a time
horizon of 10 years.22
Assessment of clinical effectiveness
Disease progression. The primary clinical effective-
ness outcome of the RSS was disease progression
measured as an accumulation of disability. This
was measured in two ways: through progression
measured on the EDSS and through utilities to pro-
vide a measure of quality of life (derived from EDSS
scores based on surveys conducted by the MS
Trust).20 These outcomes were expressed in two dif-
ferent ways: as a progression ratio and as an implied
hazard ratio (HR). The progression ratio was the ratio
(expressed as a percentage) of the observed progres-
sion in the RSS cohort to expected progression off
treatment, as calculated by the Markov model from
the ‘virtual comparator’ cohort. Implied HRs were cal-
culated as the treatment HR that was required for the
modelled data to match the observed outcome data.
Other outcomes. The absolute reduction in EDSS
progression on therapy versus that predicted without
therapy was calculated, as was the cumulative ben-
efit of GA in EDSS years over the 10-year study.
Median time to sustained EDSS 6 was estimated by
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Weibull analysis, controlling for gender and baseline
EDSS. Waning of treatment effect over time was
evaluated for both EDSS progression and utility
loss by linear regression and also by t-test on year-
2 versus year-10 implied HRs.
Sensitivity analyses. A range of sensitivity analyses
were conducted to check the robustness of the
Markov model in terms of the GA data, similar to
those conducted on the aggregate data.21 These
included: eliminating late starters (more than
90 days between baseline assessment and therapy
initiation); including patients with switch to another
RSS DMT only (primary analysis excluded all
patients with a therapy switch); including patients
with any therapy switch; missing values for year
10 used year-9 data carried forward; and using
year 1 as the baseline.
Assessment of cost-effectiveness
Cost-effectiveness was modelled using a separate
Markov model developed for the original NICE
appraisal.23,24 The final model was adapted to use
the BCMS transition probabilities,22 costs were
inflated to 2015/16 prices,25 and the analyses run
over a 50-year time horizon. The implied HR for
utility was used as the clinical effectiveness input,
with a 50% treatment waning effect applied at 10
years.20 The list price of CopaxoneV
R
was used for all
analyses (£513.95 per 28 days/£6,701 per annum).26
Results were expressed using quality-adjusted life
years (QALYs).
Sensitivity analyses. Sensitivity analyses included
disability progression being varied to match the
95% confidence intervals (CI) of the implied
HR; the time horizon being reduced to 40, 30 and
20 years; use of UK MS Survey health state costs
(the preference of NICE in recent multiple sclerosis
appraisals),27 rather than costs derived by the School
of Health and Related Research at the University of
Sheffield (ScHARR) as part of the original NICE
appraisal, which were used in the base case;24 and
all other inputs being varied by 10%.
Analyses and modelling were conducted using Excel
2010, including Visual Basic for Applications
(VBA), and SPSS 15.0 for Windows.
Standard protocol approvals, registrations, and
patient consents
Ethical approval for the RSS was given by the South
East Medical Research Ethics Committee (MREC
2/01/78) and all patients gave written consent.22
BCMS patients gave consent to be enrolled in the
BCMS database and the University of British
Columbia’s Clinical Research Ethics Board
approved the study.22
Data availability statement
The BCMS database is held at the host institution,
and analysis and access to the data are limited to on-
site access.22 The RSS operated under the oversight
of a Steering Group representing all the parties to the
Scheme (the four UK health departments, the four
companies whose products were made available
through the Scheme, the Association of British
Neurologists, the UK MS Specialist Nurses
Association, the Royal College of Nurses, and the
MS Trust). The Steering Group was administered by
the MS Trust.
Results
Patient disposition and baseline characteristics
In total, 979 patients with RRMS were treated
with GA in the RSS, with data available from
755 patients (77.1%) at the 10-year analysis. Two
patients with secondary progressive MS (SPMS)
received treatment with GA in the RSS, but
their results were excluded from analysis. Patients
who received GA were older at disease onset
(median 30 vs. 28 years, respectively; p¼ 0.0158)
and had a higher EDSS at baseline (median 3 vs.
2; p¼ 0.0019) compared with untreated patients in
the BCMS cohort (Table 1).
Clinical effectiveness
GA was associated with a 23.3% reduction in EDSS
progression (ratio 76.7; 95% CI 69.0–84.3;
p< 0.001) and a 39.0% reduction in utility (quality
of life) loss (ratio 61.0; 95% CI 52.7–69.3;
p< 0.001) compared with no treatment (Table 2).
The implied HR was 83.5% (95% CI 78.3–88.8)
for EDSS progression and 75.0% (95% CI 69.8–
80.3) for reduction in utility loss. The results corre-
sponded to an absolute reduction of 0.36 EDSS units
versus that predicted with no therapy (1.2 actual vs.
1.5 predicted). The cumulative benefit of GA over
the 10-year study (and the basis for any cost-
effectiveness calculation over this period) was 2.4
EDSS years (95% CI 1.7–3.2). The median length
of time for the GA cohort to reach an EDSS score of
6.0 was calculated to be 12.9 years.
There was no evidence of a substantial waning of
treatment effect for GA over time (EDSS: p¼ 0.093;
utility: p¼ 0.119; Figure 1). EDSS progression and
utility progression (loss) over time for GA versus
Giovannoni et al.
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that predicted without treatment are shown in
Figures 2 and 3, respectively. To further evaluate
waning, direct comparison between implied HRs
for GA at year-2 and year-10 was conducted and
showed no significant difference in terms of utilities
(69.3% vs. 75.0%, respectively; p¼ 0.142), but a
significant difference for EDSS (74.6% vs. 83.5%;
p¼ 0.0213).
Table 1. Baseline population characteristics.
GA cohort
(n¼ 755)
BCMS cohort
(n¼ 898) p-value
Sex
- Men, n (%) 173 (23%) 232 (26%) 0.1653
- Women, n (%) 582 (77%) 666 (74%)
Age at onset, years
- Mean (SD) 30.2 (8.0) 29.2 (8.7) 0.0158
- Median (IQR) 30 (24–35) 28 (23–35)
EDSS at baseline
- Mean (SD) 2.68 (1.4) 2.44 (1.7) 0.0019
- Median (IQR)† 3 (2–4) 2 (1–3.5)
Mean (SD) follow-up 7.12 (1.3) 6.4 (3.5) <0.0001
BCMS: British Columbia Multiple Sclerosis; EDSS: Expanded Disability Status Scale; GA: glatiramer acetate; IQR:
interquartile range; SD: standard deviation.
†EDSS scores are half-integers.
Table 2. Clinical effectiveness of glatiramer acetate using 10-year data from the RSS.
Actual
progression
Predicted
progression
(untreated)
Absolute
treatment
effect
Progression
ratio (95% CI) p-value
EDSS 1.177 1.537 0.360 76.7% (69.0–84.3) <0.001
Utilities 0.081 0.133 0.052 61.0% (52.7–69.3) <0.001
CI: confidence interval; EDSS: Expanded Disability Status Scale; RSS: Risk Sharing Scheme.
Figure 1. Implied hazard ratios over 10 years for glatiramer acetate.
Linear regression: EDSS, p¼ 0.093; utilities, p¼ 0.119. Year-2 vs. year-10 (t-test): EDSS, p¼ 0.0213; utilities, p¼ 0.142.
EDSS: Expanded Disability Status Scale.
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Sensitivity analyses. The sensitivity analyses had a
relatively limited impact on the progression ratios,
particularly for elimination of late starters and
imputation of missing year-10 values, with all
results being within 8% of the primary analysis
for EDSS progression and 6% for utilities
(Table 3). The inclusion of patients who switched
treatments (either to another RSS DMT or to any
DMT) shifted the results towards a lower effective-
ness (EDSS: þ3.5–5.8%; utilities: þ3.0–5.4%),
but remained within the CIs of the primary analysis.
In contrast, the use of year-1 data as treatment
baseline led to increased effectiveness of GA
(EDSS: 69.0% vs. primary analysis 76.7% [–7.7%
improvement]; utilities: 55.2% vs. 61.0% [–5.8%
improvement]); results, again, remain within the pri-
mary analysis CIs.
Cost-effectiveness
The cost per QALY for GA was £17,841 at
CopaxoneV
R
list price during the RSS study.
Sensitivity analyses. One-way (univariate) sensitivi-
ty analysis (assessing the impact of varying one var-
iable in the model at a time) revealed that the
implied HR for utility input had a substantial
Figure 2. EDSS progression over time for glatiramer acetate versus that predicted without treatment.
EDSS: Expanded Disability Status Scale.
Figure 3. Utility progression (loss) over time for glatiramer acetate versus that predicted without treatment.
Giovannoni et al.
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impact on cost-effectiveness (Supplementary
Figure 1; Supplementary Table 1). The cost per
QALY ranged from £9,633 to £30,429 at the lower
and upper bounds of the 95% CI of the implied HR.
Updating the health state costs to those from the UK
MS Survey increased the cost per QALY to £33,308.
Other inputs had a relatively limited impact on the
cost-effectiveness of GA, with the cost per QALY
remaining below £30,000 when the time horizon was
reduced to 20 years.
Discussion
The RSS was established to provide long-term dis-
ability progression data for GA and the beta inter-
ferons, while supplying these DMTs to the UK NHS
at a cost-effective price.16 For patients with RRMS,
the final 10-year analysis supported the DMTs in
aggregate having a positive effect on long-term dis-
ability, with the Markov model producing an EDSS
progression ratio of 86% and a utility progression
ratio of 69%.21 Including all patients (RRMS and
SPMS), the cumulative benefit of the RSS DMTs
was 1.3 EDSS years and there was a median of
12.5 years to reach EDSS 6. While the benefit of
the DMTs was maintained over 10 years, there was
evidence of a waning in treatment effect over time.21
Our study has now reported the corresponding
results for GA alone.
The final, 10-year results from the RSS suggest
long-term effectiveness of GA and its ability to
slow disability progression in patients with RRMS.
GA was associated with a 23% reduction in EDSS
progression and a 39% reduction in loss of utility
compared with no treatment. The clinically relevant
outcome of time to EDSS 6 was estimated to be a
median of 12.9 years on GA therapy. Importantly,
there was no evidence of a substantial waning in
treatment effect for GA within the 10-year timescale
of the study; there was no significant trend in treat-
ment effect over time (EDSS: p¼ 0.093; utility:
p¼ 0.119), and the implied HRs (i.e. treatment
effect) at 2 and 10 years were not significantly dif-
ferent for utility loss (p¼ 0.142), albeit different for
EDSS progression (p¼ 0.0213). The sensitivity anal-
yses undertaken reinforced the validity of the results,
with none of the analyses having a meaningful
impact on the progression ratios. Other studies
have also reported the longer-term effectiveness of
GA at reducing relapses and delaying disability.28,29
At the 20-year follow-up of the US Glatiramer
Acetate Trial, the cumulative annualised relapse
rate over the entire study period in patients on GA
treatment was 0.2, with 63% of patients with an
EDSS score of <4 at baseline remaining below
EDSS 4.30
GA was calculated to be a cost-effective treatment
for RRMS in the RSS (at CopaxoneV
R
list price), with
a cost per QALY below the stringent threshold of
£20,000 (base case: £17,841). In almost all modelled
scenarios, GA remained highly cost-effective, with
the main exceptions being when using the upper
95% CI for the implied HR for utility and when
using an alternative set of health state costs
(UK MS Survey), where, in both cases, the cost
per QALY increased to approximately £30,000.
Nursing/infrastructure contributions to MS services
provided by Teva (and the other companies) were
also considered as part of the RSS methodology for
assessing cost-effectiveness of the DMTs; taking
these contributions into consideration would reduce
the cost per QALY below the current base case of
£17,841. It is worth noting that the imposed waning
assumption used in the modelling (50% step reduc-
tion at 10 years) should be questioned and may be
Table 3. Sensitivity analyses on clinical effectiveness results for glatiramer acetate.
EDSS progression ratio Utilities progression ratio
Primary analysis 76.7% (69.0%–84.3%) 61.0% (52.7%–69.3%)
Eliminating late starters* 76.7% (69.1%–84.3%) 61.2% (52.9%–69.4%)
Including patients with
switch to RSS DMT only
80.3% (72.4%–87.9%) 64.0% (55.5%–72.4%)
Including patients with any switch 82.6% (74.7%–90.2%) 66.4% (57.8%–74.8%)
Year 10 missing values# 75.9% (68.1%–83.5%) 60.2% (51.9%–68.5%)
Year 1 baseline† 69.0% (61.0%–76.9%) 55.2% (47.0%–63.4%)
*Annual follow-up date was more than 90 days after the baseline assessment date and therapy initiation. #Year 9
assessments carried forward where year 10 data were missing. †Year 1 data used as the baseline (i.e. Year 0 was
disregarded). DMT: disease-modifying treatment; EDSS: Expanded Disability Status Scale; RSS: Risk Sharing
Scheme.
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considered disproportionate for GA, with the
observed reduction in the implied HR for utility
from year 2 to year 10 being only 18.5%; again,
supporting the cost-effectiveness of this treatment.
The strengths and weaknesses of the RSS have been
discussed in a number of publications.19–24 Key
weaknesses include the facts that there was no com-
parator group, treatment allocation was non-random
(by patient and physician preference), and the avail-
ability of utility data relating to EDSS scores and
associated health state costs was somewhat limited.
The BCMS data come from an earlier period than
the RSS data and, as such, might reflect a more
severe MS population, as evidence from the placebo
arms of clinical trials have indicated a steady
improvement in the natural history of MS since the
1980s.31,32 This may represent a confounding factor
in relation to the treatment effect seen in the RSS.
However, it should also be recognised that the appar-
ent improvement in the natural history of MS might
be an artefact of evolving trial inclusion criteria and
conduct, as population-based studies, such as the
BCMS, have not shown evidence for milder progno-
sis in more recent cohorts.33 Furthermore, during the
course of the RSS the number of MS specialist
nurses employed rose from 80 to over 240 across
England and Wales.34 Although their initial key
task in the RSS was to support the administration
of injectable DMTs, patients’ treatment adherence
and monitoring of (adverse) events, the role of the
MS nurse evolved significantly such that a direct
impact of improved nursing care on disability and
utility outcomes cannot be excluded.35 While this
element of the MS RSS has been neglected in pre-
vious publications on the subject,20–22 it is evidently
of generic relevance, that is, not specific to the out-
comes for GA reported here.
The RSS was not designed to be a comparative study
and caution should be exercised when drawing any
conclusions about the relative effectiveness of the
DMTs. Although there was undoubtedly a degree
of bias in selection of treatment, the results from
the RSS reflect the real-world effectiveness of GA
within NHS practice. The aggregate RSS results
were also modelled using a multilevel model,
which provided insights into the strengths and weak-
nesses of the Markov model.21 Of note, it was found
that the Markov model was particularly strong at
modelling utility loss.21 This insight indicates that
the implied HR for utility was arguably the optimal
clinical effectiveness input for analysing cost-
effectiveness in the Markov model. Perhaps more
importantly, it also strengthens the conclusions that
can be drawn, as the utility results for GA showed a
stronger treatment effect and less evidence of
waning than did those for EDSS.
The RSS is a unique study that provides long-term
clinical and cost-effectiveness data on GA in a large
cohort of patients followed for 10 years. The RSS
demonstrates that, in a real-world setting, GA is an
effective treatment that is able to slow disease pro-
gression in RRMS, with no evidence of a substantial
waning in treatment effect over time. GA was also
shown to be a cost-effective treatment at CopaxoneV
R
list price. The RSS provides prospective, long-term
disability data, albeit with some limitations, which
are lacking for most of the other DMTs, whose long-
term benefits are inferred by their demonstration of
short-term anti-inflammatory effects.
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